The leading candidate for a malaria vaccine suffered some setbacks this week even as two World Health Organization expert panels recommended going ahead with pilot projects to test it further.
The medical charity Doctors Without Borders said it would not join any pilot projects, and a guest editorial in The New England Journal of Medicine said a new study, showing that the vaccine worked less well when parasites mutated, “should give pause” to efforts to deploy it.

The vaccine, known as RTS, S or Mosquirix, has been in development for nearly 30 years, and is further along in the approval process than any other candidate. But it is no panacea. In clinical trials, it was less than 40 percent effective even after four shots.

But because malaria kills more than 400,000 children a year and no defense against it is perfect, the vaccine is being considered as an addition to current defenses: insecticide-impregnated nets, indoor DDT spraying and rapid treatment of outbreaks before they can spread.
On Friday, the W.H.O.’s Strategic Advisory Group of Experts and Malaria Policy Advisory Committee recommended that several pilot projects be carried out in Africa to make sure the vaccine is not even less effective in real-world settings than it has been in carefully monitored clinical trials.

http://nutripotblog.com/leading-malaria-vaccine-gets-mixed-reviews/

nice one op. keep it up.

nairalandmaster:
nice one op. keep it up.

Thanks for the compliment